However, for those with chronic conditions or nutrient deficiencies, testing may be advised more frequently, based on your healthcare providers recommendation
The choice depends on whether your research requires sustained release (SubQ) or rapid onset (IM)
At the end of the week-long study, the participants' blood cell glutathione levels increased 32 percent
Despite initial pharmaceutical interest, AOD 9604 did not progress through the full clinical trial pathway required for regulatory approval, and it holds no Marketing Authorisation (MA) from the MHRA or EMA
CagriSema: 13.7% body-weight reduction and 1.91 percentage-point HbA1c reduction vs placebo
Intravenous Safety Study (2025): The most recent human study examined the safety of intravenous BPC-157 in just 2 adult participants, with doses reaching 20 mg